amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
![Amphastar Pharmaceuticals logo](/files/LOGO/1297184-AMPH.png)
Company profile
Ticker
AMPH
Exchange
Website
CEO
Jack Zhang
Employees
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
International Medication Systems, Limited • Amphastar Medication Co., LLC • Armstrong Pharmaceuticals, Inc. • Amphastar Nanjing Pharmaceuticals, Inc. • Amphastar France Pharmaceuticals, S.A.S. • Amphastar UK Limited • International Medication Systems (UK) Limited ...
AMPH stock data
Latest filings (excl ownership)
8-K
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
4 Jun 24
8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
8 May 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
Transcripts
AMPH
Earnings call transcript
2024 Q1
8 May 24
AMPH
Earnings call transcript
2023 Q4
28 Feb 24
AMPH
Earnings call transcript
2023 Q3
8 Nov 23
AMPH
Earnings call transcript
2023 Q2
8 Aug 23
AMPH
Earnings call transcript
2023 Q1
9 May 23
AMPH
Earnings call transcript
2022 Q4
28 Feb 23
AMPH
Earnings call transcript
2022 Q3
8 Nov 22
AMPH
Earnings call transcript
2022 Q2
9 Aug 22
AMPH
Earnings call transcript
2022 Q1
9 May 22
AMPH
Earnings call transcript
2021 Q4
11 Mar 22
Latest ownership filings
4
WILLIAM J PETERS
28 Jun 24
144
Notice of proposed sale of securities
27 Jun 24
4
Mary Z. Luo
11 Jun 24
4
Floyd F. Petersen
11 Jun 24
144
Notice of proposed sale of securities
10 Jun 24
4
Howard Lee
5 Jun 24
4
Diane G. Gerst
5 Jun 24
4
Gayle Deflin
5 Jun 24
4
Floyd F. Petersen
5 Jun 24
4
Yakob Liawatidewi
5 Jun 24
Financial summary
Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 144.53 mm | 144.53 mm | 144.53 mm | 144.53 mm | 144.53 mm | 144.53 mm |
Cash burn (monthly) | 42.17 mm | 983.50 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 289.60 mm | 6.75 mm | n/a | n/a | n/a | n/a |
Cash remaining | -145.07 mm | 137.78 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | -3.4 | 140.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
81.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 258 |
Opened positions | 101 |
Closed positions | 50 |
Increased positions | 63 |
Reduced positions | 61 |
13F shares | Current |
---|---|
Total value | 1.35 tn |
Total shares | 39.92 mm |
Total puts | 57.30 k |
Total calls | 56.60 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Jack Y. Zhang | 6.83 mm | $0.00 |
BLK Blackrock | 6.08 mm | $266.93 bn |
Vanguard | 2.73 mm | $120.05 bn |
FHI Federated Hermes Inc - Ordinary Shares | 2.08 mm | $91.21 bn |
Neuberger Berman | 1.66 mm | $72.88 bn |
STT State Street | 1.51 mm | $66.49 bn |
Fuller & Thaler Asset Management | 1.27 mm | $55.95 bn |
Dimensional Fund Advisors | 1.18 mm | $51.98 bn |
TD Asset Management | 1.01 mm | $44.38 bn |
Geode Capital Management | 866.03 k | $38.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jun 24 | Peters William J | Common Stock | Sell | Dispose S | No | Yes | 41.2946 | 635 | 26.22 k | 94,103 |
27 Jun 24 | Peters William J | Common Stock | Sell | Dispose S | No | Yes | 40.8467 | 2,961 | 120.95 k | 94,738 |
10 Jun 24 | Floyd F. Petersen | Common Stock | Sell | Dispose S | No | No | 41.4 | 3,000 | 124.20 k | 78,409 |
10 Jun 24 | Jack Y. Zhang | Common Stock | Option exercise | Acquire M | No | No | 14.69 | 100,000 | 1.47 mm | 2,533,554 |
10 Jun 24 | Jack Y. Zhang | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 14.69 | 100,000 | 1.47 mm | 390,477 |
4 Jun 24 | Liawatidewi Yakob | Common Stock | Payment of exercise | Dispose F | No | No | 42.22 | 272 | 11.48 k | 74,938 |
3 Jun 24 | Zasloff Michael A | Common Stock | Grant | Acquire A | No | No | 0 | 3,076 | 0.00 | 24,402 |
3 Jun 24 | Zasloff Michael A | Stock Option Common Stock | Grant | Acquire A | No | No | 42.25 | 6,864 | 290.00 k | 6,864 |
News
Needham Reiterates Hold on Amphastar Pharma
22 May 24
Amphastar Bags FDA Approval for Albuterol Sulfate Inhalation Aerosol
22 May 24
Needham Reiterates Hold on Amphastar Pharma
9 May 24
Amphastar Pharma Q1 2024 Adj EPS $1.04 Beats $0.77 Estimate, Sales $171.800M Miss $174.713M Estimate
8 May 24
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
1 May 24
Press releases
BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
14 Jun 24
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
4 Jun 24
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
3 Jun 24
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
22 May 24
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
9 May 24